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Transmission of HIV-1 generally results from 
virus exposure at mucosal surfaces followed 
by virus replication in submucosal and locore-
gional lymphoid tissues, and subsequently, by 
overt systemic infection (1–7). Because of the 
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Identification of full-length transmitted HIV-1 genomes could be instrumental in HIV-1 
pathogenesis, microbicide, and vaccine research by enabling the direct analysis of those 
viruses actually responsible for productive clinical infection. We show in 12 acutely infected 
subjects (9 clade B and 3 clade C) that complete HIV-1 genomes of transmitted/founder 
viruses can be inferred by single genome amplification and sequencing of plasma virion RNA. 
This allowed for the molecular cloning and biological analysis of transmitted/founder viruses 
and a comprehensive genome-wide assessment of the genetic imprint left on the evolving 
virus quasispecies by a composite of host selection pressures. Transmitted viruses encoded 
intact canonical genes (gag-pol-vif-vpr-tat-rev-vpu-env-nef) and replicated efficiently in 
primary human CD4+ T lymphocytes but much less so in monocyte-derived macrophages. 
Transmitted viruses were CD4 and CCR5 tropic and demonstrated concealment of coreceptor 
binding surfaces of the envelope bridging sheet and variable loop 3. 2 mo after infection, 
transmitted/founder viruses in three subjects were nearly completely replaced by viruses 
differing at two to five highly selected genomic loci; by 12–20 mo, viruses exhibited con-
centrated mutations at 17–34 discrete locations. These findings reveal viral properties 
associated with mucosal HIV-1 transmission and a limited set of rapidly evolving adaptive 
mutations driven primarily, but not exclusively, by early cytotoxic T cell responses.
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inaccessibility of early sites of replication, the 
molecular details of HIV-1 transmission and 
early virus evolution remain largely unknown. 
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e1274 TRANSMITTED/FOUNDER VIRUSES IN ACUTE HIV-1 INFECTION | Salazar-Gonzalez et al.
RESULTS
Study subjects
Plasma specimens from 12 adult subjects (10 male and 2 
female) with acute HIV-1 infection were analyzed in this study 
(Table I). Nine subjects were infected by HIV-1 subtype B 
and three were infected by subtype C. At the initial sampling 
time point, 10 subjects were plasma vRNA+/Ab (Fiebig 
stage II; the HIV-1 clinical staging system is discussed in refer-
ences 11, 17), and two subjects were vRNA+/ELISA+/WB 
indeterminant (Fiebig stage IV). Three subjects were sampled 
longitudinally through as many as 85 wk of follow-up. Peak 
plasma viral loads ranged from 394,649 to 26,700,000 vRNA 
copies per ml. Four subjects admitted to heterosexual expo-
sure as their only HIV-1 risk factor, and eight were men who 
had sex with men. No subject admitted to injecting drug use.
SGA and sequencing
Between 5 and 18 complete viral genomes (median = 9) were 
derived by amplification of individual plasma vRNA/cDNA 
molecules from each subject (108 amplicons in total; Table II). 
Each of the 108 amplicons was sequenced directly without 
interim cloning. Sequence chromatograms of 62 amplicons 
were unambiguous at every position. Sequence chromato-
grams of 46 amplicons had mixed bases at one to five posi-
tions per sequence. Because the proportion of PCR-positive 
wells at endpoint cDNA dilution was <20%, and because 
mixed bases generally represented only a subset of polymor-
phisms in any one sequence, we could infer that most mixed 
bases on chromatograms resulted from Taq polymerase errors 
in the initial PCR cycles and not from amplification from 
more than one original vRNA/cDNA template; in such cases, 
a correct assignment of the ambiguous base could be made. In 
five instances where one or more mixed bases represented the 
only polymorphisms in a sequence, this was not possible. 
Thus, we could make an unambiguous assignment of nucleo-
tides at each position in the nucleotide sequences of 103 
HIV-1 genomes and at all but nine positions in five others. 
From three subjects (CH40, CH58, and CH77), an additional 
209 overlapping half genomes and 177 shorter sequence frag-
ments were determined from time points beginning before 
first antibody detection (Fiebig stage II) and extending to 
350–592 d later (Fiebig stage VI).
HIV-1 diversity
In a maximum likelihood phylogenetic tree, viral sequences 
from the nine US subjects clustered significantly with proto-
type B clade viruses, whereas sequences from the three Zam-
bian subjects clustered with prototype C clade viruses (Fig. 1). 
Maximum interstrain diversity among all 108 full-length ge-
nomes was >25%, reflecting differences typically observed 
between different clade B and C viruses. Within individual 
subjects, maximum virus diversity was far less, ranging from 
0.04% in subject SUMA0874 to 2.46% in subject ZM247F 
(Table II). There was no interspersion of sequences among 
study subjects. Maximum within-patient viral diversity was 
distinctly lower in 11 subjects (<0.14% in each) compared 
Analysis of individual HIV-1 genes from viruses that are re-
sponsible for productive clinical infection in humans can 
be instrumental in elucidating viral properties and biological 
events underlying the transmission process (8–12). However, 
identification and characterization of full-length genomes 
from such viruses could go much further in elucidating, 
on a genome-wide basis, those properties of transmitted/
founder viruses and their progeny that are essential for virus 
transmission and the establishment of viral persistence. This 
is true for naive individuals who become infected by HIV-1   
and for subjects who are immunized with candidate HIV-1 
vaccines but experience breakthrough infection (http://www 
.hvtn.org/science/1107.html).
Recently, we developed a mathematical model of HIV-1 
sequence evolution in acute infection and an experimental strat-
egy based on single genome amplification (SGA) of plasma 
vRNA/cDNA, followed by direct sequencing of uncloned 
DNA amplicons, that allowed us to infer the nucleotide se-
quences of full-length envelope (env) genes of transmitted/
founder viruses in 98 out of 102 consecutively studied patients 
(11). The model assumes that a transmitted virus replicates 
exponentially with a generation time of 2 d (13), a reproduc-
tive ratio (R0) of 6 (14), and an RT error rate of 2.16 × 105 
(15); that it diversifies under no selection; and that it exhibits 
a constant mutation rate across positions and lineages and un-
dergoes no back mutations. These assumptions were based 
on estimated parameters of virus replication and a timing of 
virus sampling before the development of detectable immune 
responses (11, 16–20). The model predicts a Poisson distribu-
tion of mutations and a star-like phylogeny that coalesces to 
an inferred consensus sequence at or near the time of virus 
transmission. We obtained direct experimental evidence in sup-
port of this model in Indian rhesus macaques mucosally infected 
by simian immunodeficiency virus (SIV) strain SIVmac251 (21) 
and in humans infected by HIV-1 from a known sexual part-
ner (unpublished data) (9). In each case, an env sequence in 
the SIV inoculum stock or in the blood of a chronically 
infected sexual partner was found to be identical to that of 
the transmitted/founder virus identified in the recipient. We 
also tested the model by Monte Carlo simulation and against 
an empirical dataset of 3,449 SGA-derived complete env 
sequences (11). The results supported the model and its as-
sumptions. Importantly, the model and the empirical findings 
allowed us to infer that in 70–80% of the cases of sexual 
transmission of HIV-1, a single virus (or infected cell) is respon-
sible for establishing productive clinical infection, a conclusion 
now supported by studies in seven additional patient cohorts 
infected by HIV-1 subtypes A, B, C, or D (unpublished data) 
(8–10, 12). In the present study, we asked if the experimental 
strategy  for  identifying  transmitted/founder  env  sequences 
can be applied successfully to full-length HIV-1 vRNA 
genomes, which are nearly four times longer than env genes 
(9 vs. 2.6 kb), and whether identification of such genomes 
can provide new insight into the biology of HIV-1 transmis-
sion, and the kinetics and pathways of virus diversification 
and adaptation leading to viral persistence.JEM VOL. 206, June 8, 2009 
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other by an average of 2.4% (Fig. 1). Sequence diversity 
within lineage 1 ranged from 0.01–0.09%, and within lineage 
2 from 0.02–0.08%. Within each lineage, sequences exhibited 
a star-like phylogeny and a Poisson distribution of mutations. 
Model estimates for time from a MRCA for lineage 1 was 21 d 
(95% C.I. = 14–28 d), and for lineage 2 was 21 d (95% C.I. = 
14–28 d). Based on this analysis, we concluded that ZM247F 
had most likely been infected by two viruses at the same time 
and from the same sexual partner (Fig. 1 and Table II).
Model testing and analysis of HIV-1 evolution
To explore how full-length HIV-1 genomic sequences sam-
pled near peak viremia conform to model predictions, we 
obtained for each subject the frequency distribution of all in-
tersequence Hamming distances (HDs; defined as the number 
of base positions at which two genomes differ) and deter-
mined whether it deviated from a Poisson model by using a 
2 goodness of fit test. Four sequences from three subjects 
exhibited G-to-A hypermutation. Once these were elimi-
nated from the analysis, sequences from 11 out of 12 subjects 
conformed to the Poisson model (Table II). Sequences from 
subject ZM247F did not conform to a Poisson model of vari-
ation but did so once the two low diversity lineages evident 
in the phylogenetic tree (Fig. 1) were analyzed individually. 
We next investigated whether or not sequences evolved under 
a star-phylogeny model (i.e., all observed sequences coalesce 
at the founder) in the expected time frame based on Fiebig 
stage. Sequences from 6 out of 12 subjects, including each lin-
eage in subject ZM247F, exhibited a star phylogeny (Table II). 
Among the samples that deviated from a star phylogeny were 
sequences from two subjects (CH40 and CH77) that exhib-
ited early changes in potential or confirmed CTL epitopes cor-
responding to the HLA types of these subjects (see Goonetilleke 
with the 12th subject, ZM247F (2.46%). We postulated that 
the observed differences in maximum viral diversity observed 
within individuals might reflect the numbers of viruses re-
sponsible for establishing productive infection in these sub-
jects, as shown previously for env diversity (11). We formally 
tested this hypothesis by comparing observed viral genome 
diversities in each subject with estimates, based on model pre-
dictions, of the maximum diversity one could expect within 
100 d after transmission of a single virus (0.60%; 0.54–0.68% 
confidence interval [C.I.]) (11). 11 out of the 12 subjects had 
sequences that fell well below the 0.6% threshold, whereas 1 
subject (ZM247F) had sequences that fell far above it (Table II). 
We also used the model to estimate in each subject the mini-
mum number of days that would be required to explain the 
observed within-patient HIV-1 genome diversification from 
a single most recent common ancestor (MRCA) sequence, 
as we had done previously for env diversification (11). In this 
analysis, we did not adjust for mutations that are selected 
against and go unobserved because they result in unfit viruses; 
as a consequence, the timing estimates based on a compari-
son of the observed data to the model tend to be biased to-
ward a low estimate. 11 subjects with lower viral diversity had 
minimum estimates for days since a MRCA virus that fell well 
within model predictions for infection by a single virus (11–
33 d; 95% C.I. = 7–38 d) and within a time frame consis-
tent  with  each  subject’s  Fiebig  clinical  stage  (Table  II). 
Conversely, sequence diversity in subject ZM247F corre-
sponded to a minimum estimate for a MRCA of 493 d, far 
beyond the range of plausibility for recent infection based on 
this subject’s Fiebig stage II, which has an average duration 
from virus transmission of 22 d (95% C.I. = 16–39 d) (11, 17). 
Interestingly, sequences from ZM247F fell into two distinct 
low diversity phylogenetic lineages that differed from each 
Table I.  Subject demographics, risk group, and baseline laboratory data
Subject HIV-1 
subtype
Geographic 
location
Gender Risk group Sampling 
date
VL Clinical 
specimen
EIA WB Fiebig 
stagea
WITO4160 B Alabama M Heterosexual 08.04.00 325,064 Plasma neg neg II
SUMA0874 B Alabama M MSM 05.13.91 939,260 Plasma neg neg II
WEAU0575 B Alabama M MSM 05.30.90 216,415 Plasma neg neg II
TRJO4551 B Alabama M MSM 10.10.01 8,121,951 Plasma neg neg II
04013226-2 B New York M MSM 11.20.02 26,700,000 Plasma neg neg II
04013396-0 B New York M MSM 08.16.05 1,600,000 Plasma pos ind IV
CH40 (700010040) B North Carolina M MSM 07.11.06 2,197,248 Serum neg neg II
CH40 (700010040) 07.27.06 298,026 Plasma pos pos (p31) V
CH58 (700010058) B North Carolina M MSM 08.22.06 92,581 Serum neg neg II
CH58 (700010058) 08.31.06 394,649 Plasma pos neg III
CH77 (700010077) B North Carolina M MSM 08.25.06 3,565,728 Serum neg neg II
CH77 (700010077) 09.08.06 144,145 Plasma pos pos (p31) V
ZM246F C Zambia F Heterosexual 01.14.03 10,013,800 Plasma neg neg II
ZM249M C Zambia M Heterosexual 08.05.03 >2,000,000 Plasma pos ind IV
ZM247F C Zambia F Heterosexual 10.28.03 10,823,500 Plasma neg neg II
EIA, enzyme-linked immunosorbant assay for HIV-1; ind, indeterminant; MSM, men who have sex with mena; VL, viral load (RNA molecules/ml); WB, Western blot for HIV-1.
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subject; median = 8) compared with env-only sequences (an 
average of 36 per subject; median = 34), were the estimated 
days since a MRCA comparable between the two datasets? 
Again, the answer was affirmative, with C.I.s for the MRCAs 
overlapping in every subject except one (Table S1).
For each subject, we examined gag, pol, env, and nef genes 
individually for levels of genetic diversity (Table S1). Within 
individual subjects, there was considerable heterogeneity 
among genes in their levels of variation, a finding largely at-
tributable to relatively short gene lengths, small numbers of 
sequences examined, and the overall low degree of viral diver-
sity present in acute infection samples. Three individuals 
lacked any variability in gag or nef sequences. The maximum 
pairwise HD was greatest in pol (6 in subject CH77) and env 
(6 in subjects 04013226-2 and CH77). Estimates of days since 
the MRCA varied among genes, with env and nef generally 
agreeing well with the estimates based on greater numbers of 
et al. [22] on p. 1253 of this issue). When putative CTL escape 
mutations and rare shared polymorphisms arising from early 
stochastic nucleotide substitutions (11) were excluded from 
the analysis, sequences from the remaining six subjects con-
formed to a star phylogeny.
We next analyzed the diversity among env genes within 
full-length genomes compared with a much larger number of 
env genes amplified as env-only sequences from the same sub-
jects (Table S1). Because the latter sequences were amplified 
using different primers than were used for complete genomes, 
the first question posed was whether both sets of sequences 
coalesced phylogenetically to the same env (or envs) within 
each subject, as would be expected for sequences emanating 
from the same transmitted/founder viruses. This was the case 
in each of the 12 subjects. The second question posed was, 
given that there were fewer env sequences derived from full-
length genomes available for analysis (an average of 11 per 
Table II.  Diversity analysis of full-length HIV-1 genomes derived from patients with primary infection
Number of 
transmitted 
viruses
Subject Fiebig 
stage
Total 
number 
of HIV-1 
genomes
Maximum 
nt length 
of viral 
genome 
analyzed
Minimum 
nt length 
of viral 
genome 
analyzed
Number 
of 
genomes 
analyzeda
Nucleotide 
sequence 
diversity 
(mean %)
Nucleotide 
sequence 
diversity 
(range %)
Max  
HD
Poisson 
estimated 
days since 
MRCAb
Lambdac Goodness 
of fit p-
value
HD fit 
to 
Poisson
Star 
phylogeny
Deviation 
from star 
phylogeny
env-only 
analysisd
Full-
length 
genome 
analysis
WITO4160 II 18 9,027 7,698 14 0.04 0–0.09 8 17 (12, 22) 3.57 0.923 Yes Yes 1 1
SUMA0874 II 6 9,033 9,020 6 0.03 0.01–0.04 4 11 (7, 15) 2.33 0.546 Yes Yes 1 1
WEAU0575 II 9 9,028 9,022 9 0.03 0–0.08 7 14 (8, 21) 3.06 0.49 Yes No Early 
stochastic
1 1
TRJO4551 II 7 9,051 9,046 7 0.06 0.03–0.07 7 20 (14, 26) 4.29 0.836 Yes Yes 1 1
04013226-2 II 9 9,068 9,038 8 0.08 0.04–0.11 10 33 (28, 38) 7.04 0.269 Yes No Early 
stochastic
1 1
04013396-0 IV 5 9,049 9,048 4 0.03 0–0.06 5 12 (7, 17) 2.5 0.704 Yes Yes   1 1
CH40  
(700010040)
II 26e 3,593 2,977 26 0.04 0–0.11 4 16 (12, 21) 1.372 0.251 Yes Yes 1 1
CH40 
(700010040)
V 9 8,990 8,989 9 0.05 0.01–0.1 9 21 (14, 28) 4.44 0.46 Yes No CTL selection 1 1
CH58 
(700010058)
III 7 9,027 8,717 7 0.06 0.02–0.1 9 24 (14, 33) 5.05 0.941 Yes No Early 
stochastic
1 1
CH77 
(700010077)
II 23e 2,785 2,785 23 0.05 0–0.14 4 20 (13,26) 1.3 0.449 Yes Yes 1 1
CH77 
(700010077)
V 8 9,048 9,037 8 0.06 0.02–0.13 12 27 (16, 37) 5.75 0.46 Yes No CTL selection 1 1
ZM246F II 10 8,978 8,977 10 0.04 0–0.09 8 17 (10, 24) 3.56 0.88 Yes No Early 
stochastic
1 1
ZM249M IV 7 9,054 8,735 7 0.03 0.01–0.06 5 15 (9, 20) 3.1 0.671 Yes Yes   1 1
ZM247F II 13 9,040 7,957 12 1.19 0.01–2.46 220 493 (314,  
 673)
106.197 0 No No Two strains 2 2
ZM247F lng 1f II 9 9,040 7,957 8 0.05 0.01–0.09 8 21 (14, 28) 4.5 0.967 Yes Yes 1 1
ZM247F lng 2f II 4 9,034 9,033 4 0.05 0.02–0.08 7 21 (14, 28) 4.5 0.939 Yes Yes   1 1
aGenomes with multiple APOBEC G-to-A hypermutations or large deletions were excluded from model analysis.
bPredicted minimum number of days needed to achieve observed within-patient diversity.
cMean of best fitting Poisson distribution. Lambda is the free parameter that defines a Poisson.
dEnv-only analyses were previously reported (unpublished data) (11, 12).
eSGA sequences representing 3 half subgenomic fragments from the screening sample.
flng 1= lineage 1; lng 2= lineage 2.JEM VOL. 206, June 8, 2009 
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env-only sequences. Contrary to an earlier study (23), there 
was no evidence of greater variability in gag compared with 
env. Table S2 shows the total number of synonymous and non-
synonymous differences among all sequences for each subject 
and for each gene. There was an excess of nonsynonymous 
substitutions. However, when taking into account that most 
random replacements in a coding sequence are nonsynony-
mous (79%), the rate of synonymous divergence (ps) tended 
to exceed that of the nonsynonymous divergence (pn) for 
each gene suggestive of purifying selection. This difference 
did not reach statistical significance in the present study but 
did reach significance in a previous one where far greater 
numbers of sequences were available for analysis (11, 24).
Identification of transmitted or early founder viral genomes
Fig. 2 illustrates the phylogeny of full-length viral sequences 
from subject WITO4160 together with Highlighter plots 
depicting the positions and identities of nucleotide polymor-
phisms, insertions, and deletions across the genomes. Among 
the 18 WITO4160 sequences, no two were identical. Seven 
sequences contained a total of 15 mixed bases due primarily, 
if not exclusively, to Taq polymerase errors in the initial one 
or two cycles of PCR amplification. This experimental result 
(15 Taq errors in 18 genomes × 9,000 bp per genome × 3 DNA 
strands synthesized in the initial two complete cycles of Taq 
polymerization = 3 × 105) is consistent with the error rate 
reported for Taq polymerase of 2.7–8.5 × 105 (25). Exclud-
ing mixed bases (which are denoted by an International 
Union of Pure and Applied Chemistry designation), single 
nucleotide insertions (C1, C10, B3, and C9), large deletions 
(G7 and C4), and G-to-A hypermutation (H3 and C3), each 
of the sequences differed from the others by 0–11 nt. Nucleo-
tide substitutions exhibited a Poisson distribution and star-
like phylogeny (Table II). The consensus of the sequences 
(WITO_fl.CON) was the same whether or not sequences 
containing double peaks were included in the analysis; this is 
an expected result because Taq polymerase errors, like HIV-1 
RT errors, are essentially randomly distributed across the ge-
nomes. Out of the 18 genomes, 9 had intact open reading 
frames for all essential viral genes, whereas 9 others contained 
stop codons or insertions or deletions ranging in length from 
1 to 1,329 nt. Fig. 3 illustrates in a second subject, ZM247F, 
many of the same features of early virus diversification, but 
from two transmitted/founder viruses rather than one. Each 
transmitted/founder virus in ZM247F was represented by a 
distinct low diversity lineage evident in both the phyloge-
netic tree and the Highlighter plot. Among all 13 sequences, 
no two were identical. 8 out of 13 sequences contained mixed 
bases at one or two positions. Nine sequences contained all 
essential open reading frames intact. 3 out of 13 sequences 
contained deletions of between 1 and 1,083 nt; one addi-
tional sequence contained a nucleotide substitution resulting 
Figure 1.  Maximum likelihood phylogenetic tree of full-length 
HIV-1 genome sequences from 12 subjects. Individual sequences are 
shown as filled ovals. HIV-1 clade B and C reference sequences from the 
LANL database (http://www.hiv.lanl.gov/content/index) are shown in gray. 
Numerals at nodes indicate phylogenetic support for sequences included 
at that node; maximum likelihood bootstrap support ≥ 70% is shown in 
italics. Bayesian posterior probability values ≥ 0.9 are shown in bold. The 
scale bar indicates 5% genetic distance (5 nt differences per 100 sites).
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many mutations that occur with sequential replication cycles 
provides a selective advantage to the virus that results in rapid 
preferential accumulation of its progeny; this is a particularly 
likely scenario for CH40 and CH77 at Fiebig stage V, where 
in a separate study we identified early virus-specific CTL 
responses (22). In subjects CH40 (Fig. 4 A), CH77 (Fig. 4 B), 
CH58, ZM246F, 04013226-2, and WEAU0575 (Fig. S2), 
shared polymorphisms initially precluded a definitive identi-
fication of transmitted/founder virus sequences, but this un-
certainty could be resolved by analysis of viral sequences from 
earlier or later time points. This is because a clear directional-
ity in shifting proportions of shared polymorphisms could be 
established. In subject CH40, for example, where three shared 
polymorphisms at position 6,705 (G) in env and positions 
9,360 (A) and 9,371 (A) in nef (Figs. 4 A and 5 A; and Fig. S3) 
were evident in the Fiebig stage V sample, analysis of sequences 
obtained from a still earlier plasma specimen when the sub-
ject was at Fiebig stage II revealed no polymorphisms in nef. 
4, 12, 24, and 60 wk after enrollment, 63 out of 63 (100%) 
sequences carried mutations at the two polymorphic sites in nef, 
or within a 30-nt sequence spanning them (Fig. 5 A and 
Fig. S3). Thus, it was obvious from this analysis that the 
transmitted/founder sequence at these polymorphic nef posi-
tions was represented by sequence CH40_fl.CON (Fig. 4 A). 
We interrogated the shared polymorphism in env in a similar 
manner. In this case, however, 0 out of 26 sequences from 
the earliest Fiebig stage II sample, 6 out of 23 (26%) sequences 
in a translational stop codon. Neither APOBEC-related   
G-to-A hypermutation nor viral recombination between lin-
eages was observed in these very early ZM247F sequences. 
Sequences comprising each viral lineage (with or without mixed 
bases included) coalesced to unique, unambiguous transmitted/
founder genomes that differed by 2.36%.
Sequences from each of the two viral lineages in ZM247F 
and from the single lineages in WITO4160, SUMA0874, 
TRJO4551, 04013396-0, and ZM249M exhibited Poisson 
distributions of mutations and star-like phylogenies (Figs. 2 
and 3; Fig. S1; and Table II), thus allowing for a definitive 
identification of the transmitted/founder viruses in each sub-
ject. Sequences from six other subjects, however, exhibited 
shared polymorphisms, which can confound the identification 
of transmitted/founder sequences (11). Examples of shared 
polymorphisms are illustrated in Fig. 4 for subjects CH40 
and CH77, each of whom had just entered Fiebig stage V 
(vRNA+/ELISA+/WB+[P31–]) at the time of sampling of 
these sequences. Three shared polymorphisms were evident 
in sequences of subject CH40 (Fig. 4 A) and five were evi-
dent in subject CH77 (Fig. 4 B). Shared polymorphisms can 
result if two very closely related viruses are acquired during 
the transmission event, most commonly from a donor who 
himself/herself is acutely infected (11), or they can arise as a 
consequence of RT errors in early virus replication cycles of 
a single transmitted virus and persist alongside the transmitted 
viral lineage (11). A third possibility is that one or more of the 
Figure 2.  Phylogenetic and Highlighter analyses of HIV-1 sequences from subject WITO4160. WITO_fl.CON is the inferred transmitted/founder 
sequence. In the phylogram (left), asterisks indicate sequences that had International Union of Pure and Applied Chemistry ambiguous state assignments 
caused by mixed bases. Mixed bases were attributed to Taq polymerase errors and, thus, are not reflected in branch lengths of phylograms in this or other 
figures. The scale bar indicates a genetic distance of 0.0001 (0.01%, or 1 nt difference per genome). In the Highlighter plots (middle and right), nucleotide 
differences from the transmitted/founder consensus sequence are indicated by tic marks. Brackets denote insertions of single bases. Gray tics and boxes 
indicate a deleted sequence. The consensus (CON) is the same whether or not mixed bases are included. The middle Highlighter plot shows sequences 
without ambiguous (mixed) base assignments. The Highlighter plot on the right includes sequences with one or more ambiguous bases (shown as dark 
blue tic marks). Sequences H3 and C3 contained APOBEC-related G-to-A hypermutation. The horizontal axis indicates nucleotide positions in the HIV-1 
genome. Sequences begin at nucleotide position 582 in the 5 LTR (U5) and extend to position 9,606 in the 3 LTR (R) based on HXB2 reference sequence 
numbering (http://www.hiv.lanl.gov/content/sequence/HIV/REVIEWS/HXB2.html).JEM VOL. 206, June 8, 2009 
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that 23 out of 23 (100%) earlier Fiebig II sequences were iden-
tical at position 6,021 (containing a T residue) and in a 30-nt 
region spanning it, and that they were different from 90 out of 
92 (98%) sequences from the subsequent time points in this 
same region (Fig. S4). Thus, at position 6,021, sequences 
CH77E_fl.C7 and CH77E_fl.C3 corresponded to the trans-
mitted/founder virus. The three other shared polymorphisms 
in pol at positions 2,625, 4,021, and 4,104 represented uncom-
mon sequences in the Fiebig stage V sample that were not 
prominent in earlier or later samples (Fig. S5 and not de-
picted). Thus, they represented stochastic mutations that 
occurred sometime shortly after transmission and persisted at a 
detectable frequency only transiently. From these analyses, we 
could infer that none of the sequences shown in Fig. 4 B cor-
responded to the transmitted/founder genome in subject 
CH77. Instead, the transmitted/founder full-length genome 
in subject CH77 corresponded to a sequence identical to the 
CH77E_fl.A2 sequence except for a single C to T substitution 
at position 6,021. Full-length genomes from subject CH58 at 
Fiebig stage III contained two out of seven sequences with a 
single polymorphism (C) at position 4,408 in pol (Fig. S2 B). 
By examining 12 sequences from Fiebig stage II 9 d earlier and 
23 sequences from 45–350 d later (Fig. S6), we could establish 
definitively the transmitted/founder sequence. The full-length 
transmitted/founder virus genomes for CH40, CH77, and 
CH58 represented in Fig. 5 reflect these phylogenetic infer-
ences. For four other subjects whose sequences exhibited rare 
shared polymorphisms and where very early (Fiebig stage II) 
or sequential samples were available for analysis, all showed 
evidence that their consensus sequences indicated in Fig. S2 
corresponded to transmitted/founder viruses. Thus, in 12 out 
of 12 study subjects, we could identify with a high level of 
confidence the transmitted/founder viral genomes.
from the Fiebig V sample, and 0 out of 63 sequences from 
samples 4, 12, 24, or 60 wk later contained the shared poly-
morphism (Figs. 5 A and S3). Thus, this shared nucleotide 
polymorphism represented an early stochastic mutation that 
in all likelihood occurred shortly after virus transmission as 
predicted in the model (11), was represented as a minor pop-
ulation in the earliest samples, exhibited no fitness advantage, 
and did not accumulate; instead, it was lost as a minor variant in 
the expanding quasispecies. Thus, in subject CH40, we could 
conclude definitively that the transmitted/founder virus ge-
nome was represented by the CH40_fl.CON sequence.
Five  shared  polymorphisms  in  subject  CH77  could  be 
similarly deconvoluted and the transmitted/founder virus 
identified (Fig. 4 B). The initial sample that we analyzed from 
this subject was also obtained at early Fiebig stage V, similar to 
the enrollment sample of subject CH40. At this time point at 
position 7,285 in env, 49 out of 66 (74%) CH77 sequences 
shared a common nucleotide (A), whereas 17 others shared a 
different nucleotide (16 sequences with G and 1 sequence 
with C; Fig. S4). 14 d earlier when the patient was at Fiebig 
stage II, 23 out of 23 sequences were identical in having a G 
at this position (Fig. S4). 3–24 wk after enrollment, 29 out of 
29 (100%) sequences contained nucleotide mutations at this 
position or within a 30-nt span that encompassed it. Thus, we 
could conclude that the transmitted/founder sequence at this 
position was represented by CH77E_fl.A2 and not by what 
was the consensus sequence at the enrollment time point 
(Fig. 4 B). A second set of shared nucleotide polymorphisms 
was evident in tat sequences (position 6,021) where two full-
length genomes (C7 and C3) shared a common (T) polymor-
phism. We could resolve which sequence represented the 
transmitted/founder virus by determining viral sequences 14 d 
before and 3–24 wk after this time point. The results revealed 
Figure 3.  Phylogenetic and Highlighter analyses of HIV-1 sequences from subject ZM247F. Subject ZM247F had sequences comprising two 
distinct lineages that were 2.4% different from each other, as shown by the phylogram (left) and Highlighter plot (right). ZM247F_fl.CON1 is the consen-
sus of lineage 1. The second lineage (sequences B8, E10, E11, and G11) differs from ZM247F_fl.CON1 by 213–217 nt differences, as indicated by tic marks.1280 TRANSMITTED/FOUNDER VIRUSES IN ACUTE HIV-1 INFECTION | Salazar-Gonzalez et al.
founder viruses for subjects ZM246F and ZM247F were con-
structed either by chemical synthesis or by PCR amplifica-
tion of viral nucleic acid followed by cloning into plasmid 
expression vectors (Fig. 6 A). All three genomes (pZM246F-10, 
pZM247Fv1, and pZM247Fv2) yielded replication-compe-
tent virus after transfection and expression in human 293T 
cells. Each of the three virus strains replicated in activated 
primary human CD4+ T lymphocytes with kinetics and yields 
comparable to six control viruses (YU2, SG3, NL4.3, BaL, 
ADA, and JRCSF) (Fig. 6 B). Surprisingly, each of the three 
transmitted/founder  viruses  failed  to  replicate  efficiently 
when passaged onto human monocyte-derived macrophages 
obtained from the same normal donor, whereas three proto-
typic primary macrophage-tropic control viruses (YU2, BaL, 
and ADA) used as positive controls replicated efficiently in 
both cell types (Fig. 6 B). This experiment was repeated four 
times using four different normal uninfected blood donors as 
the source of lymphocytes and monocyte-derived macro-
phages and using virus initially generated either in 293T cells 
Genetic and biological analysis of transmitted/founder viruses
If early viral sequences coalesce to actual transmitted/founder 
viruses responsible for productive clinical infection, then we 
would expect three predictions to be borne out experimen-
tally:  (a)  transmitted/founder  env  sequences  inferred  from 
full-length viral genome analysis must be identical to trans-
mitted/founder  sequences  inferred  from  env-only  (subge-
nomic) SGA analysis; (b) all essential viral gene open reading 
frames in transmitted/founder full-length genomes must be 
intact; and (c) inferred transmitted/founder full-length genome 
sequences must encode replication-competent viruses. We 
tested and affirmed all three predictions: first, consensus trans-
mitted/founder env genes derived by subgenomic amplifica-
tions of env and by full genome amplifications were identical 
in each of the 12 subjects (Table II). Second, transmitted/
founder complete genomes from each of the 12 subjects con-
tained intact gag, pol (rt, pro, and int), vif, vpr, tat, rev, vpu, env, 
and nef open reading frames. Third, three complete HIV-1 
clade C proviral genomes corresponding to transmitted/
Figure 4.  Phylogenetic and Highlighter analyses of HIV-1 sequences. (A and B) Analyses are from subjects CH40 (A) and CH77 (B). In Highlighter 
plots, the boxed tic marks indicate nucleotide polymorphisms shared between two or more sequences. Such shared mutations are also reflected by branches 
emanating from common nodes in the phylograms. In B, sequences are rooted on sequence A2, not on a consensus of the sequences. This is because se-
quence A2 was most similar to the transmitted/founder sequence, differing from it by only a single nucleotide at position 6,021 (see Results for explanation).JEM VOL. 206, June 8, 2009 
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or in activated human lymphocytes, each time with similar 
results. Seven molecular clones of full-length clade B trans-
mitted/founder viruses were also generated as part of a sepa-
rate study and were tested for replication in human cells 
(unpublished data). These transmitted/founder viruses repli-
cated efficiently in activated CD4+ T lymphocytes but much 
less so in monocyte-derived macrophages.
To examine further the biological and antigenic properties 
of transmitted/founder viruses, we tested HIV-1pZM246F-10, 
HIV-1pZM247Fv1, and HIV-1pZM247Fv2 for sensitivity to the re-
ceptor inhibitor soluble CD4 (sCD4); coreceptor inhibitors 
TAK-779 and AMD3100; fusion inhibitors T20 and T1249; 
and mAbs specific for the Env coreceptor binding surface (17b 
and 21c), CD4 binding site (b12), V3 loop (447-52D, F425-
B4e8, and 3074), membrane proximal external region (2F5 
and 4E10), and cell-surface CD4 (RPA-T4). We also tested 
the transmitted/founder viruses for sensitivity to heterologous 
subtype B and C plasmas to assess their overall neutralization 
sensitivities. The results are summarized in Table III and show 
that the transmitted/founder viruses exhibit properties typical 
of primary virus strains including CD4 and CCR5 depen-
dence, effective concealment of the coreceptor binding bridg-
ing sheet and V3 loop structures, and generalized resistance to 
neutralization by heterologous plasma antibodies. The three 
clade C transmitted/founder viruses were, however, interme-
diately sensitive to 4E10 (IC50 = 5–48 µg/ml) and in one case 
(HIV-1pZM246F-10) to b12 (IC50 = 21 µg/ml).
Molecular pathways and kinetics of virus diversification and 
adaptation
HIV-1 virions in plasma have an exceedingly short lifespan 
(<6 h), as do productively infected lymphocytes (1 d) (13, 
26–28). As a result, the genetic composition of plasma virus can 
change quickly and can provide a sensitive indicator of selec-
tion pressures acting on virus and virus-producing cells (16, 
18, 20, 27, 28). These properties, combined with the identi-
fication  of  full-length  transmitted/founder  virus  genomes, 
provided a unique opportunity to evaluate the kinetics and 
precise molecular pathways of HIV-1 sequence diversifica-
tion and evolution on a genome-wide basis, because muta-
tions could be mapped to specific viral genomes at or near the 
moment of transmission. In none of the 12 subjects did we find 
evidence of positive selection in viral sequences obtained 
before first antibody detection (i.e., before Fiebig stage III). 
Instead, we found evidence of selection against amino acid–con-
ferring substitutions during this very early period, with pn  ps 
values tending to be less than predicted for neutral evolu-
tion (Table S2). This is an expected finding, because evo-
lutionary theory predicts most nucleotide substitutions to be 
neutral or deleterious. Early sequence diversification was no-
table for a high proportion of defective genomes: 27 sequences 
had frame-shifting insertions or deletions; 3 sequences had 
large in-frame deletions 318–1,329 nt in length; 5 sequences 
had gene open reading frames that were truncated because of 
in-frame stop codons arising from nucleotide point mutations; 
and 4 sequences contained evidence of APOBEC-mediated 
G-to-A hypermutation. Collectively, 34 out of 108 sequences 
contained mutations that rendered virus progeny overtly de-
fective. Even this high proportion of defective genomes is an 
underestimate of the actual proportion of viruses or proviruses 
that contain defective genomes, because we excluded ampli-
cons <7 kb in length and we did not examine the integrated 
proviral DNA compartment directly. In a separate study, we 
have done the latter and have found that approximately two 
thirds of HIV-1–infected cells in acutely infected subjects 
harbor overtly defective genomes (unpublished data).
We next examined sequences from a subset of subjects 
(CH40, CH58, and CH77) beginning at or near peak vire-
mia (Fiebig stage II) and extending through 12–20 mo of fol-
low-up (Fiebig stage VI). We did this first by identifying the 
transmitted/founder viral genome in each subject and then 
(using the same SGA-direct sequencing approach to avoid 
Taq-induced nucleotide substitutions and in vitro–generated 
recombination events) (12) by determining genomic sequences 
of plasma virus amplified as overlapping half genomes over 
the ensuing period (Fig. 5). In contrast to sequences obtained 
from subjects in Fiebig stage II, which generally contained 
few if any shared polymorphisms (Figs. 2 and 3; and Figs. S1 
and S2), sequences from subjects at Fiebig stages V (CH40 
and CH77) and III (CH58) exhibited shared polymorphisms 
and nonstar-like phylogenies (Figs. 4 and 5). This included 
nucleotide positions 2,625, 4,021, 4,104, 6,002, 6,021, and 
7,285 in subject CH77; nucleotide positions 6,705, 9,360 and 
9,371 in subject CH40; and nucleotide position 4,408 in sub-
ject CH58. By 32–45 d after the initial screening time point 
(labeled S in Fig. 5), clear patterns of nonrandom substitu-
tions leading to nearly complete replacement of the transmit-
ted/founder virus were evident in the sequences from each 
subject (Fig. 5). There was strong statistical evidence for posi-
tive selection in these highly focused regions that generally 
were embedded in epitopes that were early targets of the cel-
lular immune system (22). The most rapid replacement of 
transmitted/founder virus sequences by mutant virus was 
observed in subject CH77, where within a period of 2 wk 
(between screen and day 14) nearly the entire replicating virus 
population in the body that contributed virus to the plasma 
compartment was replaced by viruses that shared concentrated 
mutations in two short regions, each spanning <30 nt in 
length, in tat and env. Equally remarkable was the finding that 
this mutant virus population in CH77 was in turn completely 
replaced by still another population that contained two addi-
tional sets of concentrated mutations in nef, with each again 
spanning <30 nt (compare day 14 and 32 sequences in CH77; 
Fig. 5). In these four discreet regions of selection in tat, env, 
and nef of subject CH77, we counted a total of 22 different 
nucleotide substitutions among the sequences at days 14 and 
32. 20 out of 22 (91%) of these nucleotide substitutions were 
nonsynonymous. Selection for mutations was nearly as rapid 
in subjects CH40 and CH58 (Fig. 5), where such changes were 
first evident <9–16 d after antibody detection, which marks 
the end of Fiebig stage II and the beginning of stage III. Note 
in subject CH58 that selected mutations at positions 7,980 1282 TRANSMITTED/FOUNDER VIRUSES IN ACUTE HIV-1 INFECTION | Salazar-Gonzalez et al.
Figure 5.  Highlighter plots of sequences from longitudinal samples. (A–C) Samples were from subjects CH40 (A), CH58 (B), and CH77 (C). The dark 
line represents the transmitted/founder sequence (T/F) for each subject. Sequences from different sample dates are indicated by the grouped horizontal 
lines, with tic marks indicating differences from the T/F sequence. The screening sample (S) was in each case obtained from a preseroconversion Fiebig 
stage II sample near peak viremia. The sampling times in days after screening and corresponding viral loads are indicated (left). Light blue tic marks indicate JEM VOL. 206, June 8, 2009 
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shared nucleotide polymorphisms and mixed bases are detected 
approximately four times more frequently. Such sequence 
ambiguities or polymorphisms are predicted by the model 
(see the mathematical model in Materials and methods) (11) 
and can be problematic for the correct identification of trans-
mitted/founder viruses. However, we showed in this paper 
that they could be reconciled by the analysis of sequential 
sequences. A second and third question posed was if early di-
versification of full-length HIV-1 genomes conformed to a 
model of random evolution and if the identification of trans-
mitted/founder viruses and estimates of time to a MRCA 
based on full-genome analyses corresponded to findings based 
on env-only gene analyses? The answer to both queries was 
yes. We have corroborated these findings by additional stud-
ies where we identified the transmitted/founder virus from 
PBMC proviral DNA and plasma vRNA from the same indi-
viduals using primer sets that amplified complete viral genomes, 
5 and 3 half genomes, and env-only genomes (unpublished 
data) (9).
We also asked whether transmitted/founder full-length 
sequences have intact principal gene open reading frames and 
if they encode replication-competent viruses, as would be 
expected of transmitted/founder viruses responsible for spawn-
ing productive clinical infection? Indeed, each of the 13 
transmitted/founder genomes that we identified had intact 
gag, pol (rt, pro, int), vif, vpr, tat, rev, vpu, env, and nef genes. To 
determine if transmitted/founder genomes encoded replica-
tion-competent viruses, we selected three full-length clade 
C sequences for analysis. Obtaining full-length recombinant 
clones of proviral genomes whose sequences match exactly 
those of transmitted/founder viruses can be challenging be-
cause of errors introduced by Superscript III MuLV RT or by 
Taq DNA polymerase in individual HIV-1 genomic sequences. 
Further complicating the cloning of replication-competent 
virus is an inherent pathogenicity of some env genes when 
replicated in bacteria. We circumvented these problems by 
pursuing two different strategies. First, we chemically synthe-
sized and subcloned the complete transmitted/founder proviral 
genome of subject ZM246F in three overlapping subgenomic 
fragments, none of which included an intact env gene. The 
three fragments were cloned into a low copy number plasmid 
vector (Fig. 6 A, top), which was grown at reduced tempera-
tures and for shorter durations than normal to prevent spon-
taneous deletions or other inactivating mutations. As a second 
approach, we used the high fidelity Phusion DNA polymerase 
to amplify in two overlapping proviral half genomes (neither 
containing an intact env gene) from preseroconversion high 
molecular weight lymphocyte DNA each of the two trans-
mitted/founder viruses of subject ZM247F (Fig. 6 A, bottom). 
and 7,986 in env had begun to accumulate as plasma virus 
load was still increasing. Based on inspection of sequences 
(Fig. 5), it was apparent by 32–45 d after screen that selected 
changes had resulted in nearly complete virus replacement at 
two genomic loci in CH58 (both in env) and five loci in 
CH40 (in gag, vif, vpr, and nef). Again, it was notable that nu-
cleotide substitutions in each of these seven discreet loci were 
restricted to spans of <30 nt, and 17 out of 18 (94%) distinct 
nucleotide substitutions were nonsynonymous. The combi-
nation of a very high proportion of nonsynonymous nu-
cleotide substitutions (>90%) concentrated in short spans of 
sequence (generally <30 nt) and affecting a high proportion 
of viral genomes (>90%) argues strongly for substantial selec-
tion pressure on the replicating virus quasispecies, a conclu-
sion supported by formal statistical analysis and phenotypic 
testing (22). By 12–20 mo after infection, 17–34 discreet loci 
across the genomes showed evidence of strong mutational 
selection. Based on these findings, we concluded that the ge-
netic imprint of a composite of host selection pressures influ-
encing virus fitness in the critical period beginning at or near 
the moment of virus transmission and extending through the 
establishment of productive clinical infection and setpoint 
viremia had been captured in the sequences depicted in 
Fig. 5. In two companion studies, we show this genetic im-
print to reflect both cellular and humoral immune responses 
(unpublished data) (22).
DISCUSSION
Understanding the precise molecular and biological events 
underlying HIV-1 transmission and subsequent steps leading 
to productive clinical infection could prove valuable in the 
development of effective HIV-1 vaccines and microbicides. 
But elucidating these events in a biologically and physiologi-
cally relevant context has been problematic because neither the 
particular viruses responsible for productive infection nor their 
initial target cells were known with certainty (2, 3, 5, 6, 29). 
In this paper, we take a step toward addressing this challenge 
by showing that complete genomes of transmitted/founder 
viruses can be identified, cloned, expressed, and analyzed phe-
notypically, and their evolution mapped precisely.
The current study builds on recent studies that describe a 
model of HIV-1 evolution in acute infection (11, 21) and 
empirical analyses of early env gene or pro-pol gene diversifi-
cation (8–12, 21). We sought to extend this work to an analysis 
of full-length HIV-1 genomes and to address five questions 
specifically. First, can methods for SGA-direct sequencing of 
plasma vRNA/cDNA env sequences be applied successfully to 
full-length HIV-1 genomes? The answer is yes, but because 
of the fourfold increased length of the amplified genome, 
differences in noncoding regions of the genomes. Gray tic marks indicate deletions. Green tic marks indicate differences that are synonymous in the 
reading frames indicated at the bottom of the figure. Red tic marks indicate differences that are nonsynonymous in a coding gene. Short horizontal lines 
(labeled A, B, and C) indicate short (1-kb) sequences from a screening sample used to verify the presence or absence of a shared polymorphism (Figs. 
S3–S6). The horizontal axis indicates nucleotide positions in the alignment beginning at position 582 in the 5 LTR (U5) and extending to position 9,606 in 
the 3 LTR (R) based on HXB2 reference sequence numbering (http://www.hiv.lanl.gov/content/sequence/HIV/REVIEWS/HXB2.html).
 1284 TRANSMITTED/FOUNDER VIRUSES IN ACUTE HIV-1 INFECTION | Salazar-Gonzalez et al.
these three proviral clones replicated efficiently in activated 
primary human CD4+ T lymphocytes (Fig. 6 B, top). Surpris-
ingly, none of the three transmitted/founder viruses repli-
cated efficiently in monocyte-derived macrophages from the 
same donors (Fig. 6 B, bottom). This result was reproducible 
This was followed by ligation and cloning of the complete 
proviruses into a low copy plasmid vector. The nucleotide 
sequence of each of the three proviruses was confirmed to be 
identical to the respective transmitted/founder viral sequences. 
Progeny viruses derived from 293T cells transfected with 
Figure 6.  Cloning strategy and functional analysis of three subtype C full-length molecular clones from subjects ZM246F and ZM247F.  
(A) The full-length transmitted/founder proviral sequence for ZM246F was chemically synthesized in three overlapping fragments. The two transmitted/
founder proviruses in subject ZM247F were PCR amplified from PBMC DNA in two overlapping halves. Proviral fragments were cloned into the indicated 
plasmid vectors. (B) Plasmid DNAs were transfected into 293T cells, and progeny viruses were examined for their ability to replicate in activated primary 
human CD4+ lymphocytes (top) and monocyte-derived macrophages (bottom) from the same donor. Culture supernatants were analyzed at days 1–16 for 
p24 production. The results shown were replicated four times in lymphocytes and macrophages from four different normal blood donors.JEM VOL. 206, June 8, 2009 
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(17b and 21C) and V3 (447-52D, F425-B4e8, and 3074) 
mAbs at concentrations as high as 25 µg/ml. When CD4i and 
V3 epitopes are exposed by sCD4 binding (38, 39) or in the 
context of HIV-2/HIV-1 Env chimeras (39, 40), the five 
CD4i and V3 mAbs neutralize viruses at IC50 concentrations 
between 0.001 and 5 µg/ml, indicating that the cognate epitopes 
are present but concealed in the native Env trimer (38–40). 
These findings suggest that CD4i bridging sheet and V3 epi-
topes on native clade C Env trimers are effectively shielded, 
as they are in native clade B Env trimers (11, 38–40). Finally, 
we found that 11 clade B and 22 clade C plasmas (all heterol-
ogous and containing high titers of CD4i and V3 cross-reactive 
polyclonal antibodies) (39, 40) exhibited low Nab titers against 
the three clade C viruses (IC50 < 1:40). This again suggested 
that the functional Env trimer on these transmitted/founder 
clade C viruses is effectively masked from antibody recognition.
The last question we asked was if the identification of 
transmitted/founder full-length genomes and their progeny 
could provide new insight into the kinetics and molecular 
pathways of HIV-1 diversification and adaptation leading to 
virus persistence? Between transmission and peak viremia (Fiebig 
stage II), we found that the virus diversified in an essentially 
random fashion, leaving no or little evidence of host-related 
selective pressures imprinted on its genome. 9–16 d later, ev-
idence of striking selection on the virus quasispecies emerged 
in all three subjects studied, and by 32–45 d nearly the entire 
replicating virus population in each subject was replaced by 
viruses harboring mutations at two to five distinct loci (Fig. 5). 
In an accompanying paper, we model the kinetics and fitness 
costs associated with these rapidly evolving mutations and es-
timate the contributions of early CTL-mediated cell killing 
to virus containment (22). It is notable that for HIV-1 to es-
tablish early productive clinical infection (<3 mo from trans-
mission), as few as two to five mutations were required across 
the entire transmitted/founder virus proteome. But for chronic 
persistent replication at 6 mo after infection, some 4–14 
loci of mutational selection were evident, and by 12–20 mo 
in lymphocytes and monocyte-derived macrophages from four 
different normal uninfected donors and was subsequently cor-
roborated using viruses derived from full-length transmitted/
founder proviral DNA clones from seven clade B subjects 
(unpublished data). We note that other investigators have 
previously observed that only a subset of primary R5 tropic 
viruses replicate efficiently in human monocyte-derived macro-
phages (30–33). These findings suggest that prototypic macro-
phage-tropic HIV-1 strains such as YU2, ADA, and BaL, which 
have frequently been used to model HIV-1 transmission, 
may not be representative of a substantial proportion of trans-
mitted/founder viruses with respect to cell tropism. Our 
findings further suggest that during the initial stages of infec-
tion between transmission and peak viremia, replication of 
the transmitted/founder virus and its progeny in macrophages 
is unlikely to contribute substantially to overall virus produc-
tion compared with lymphocyte-tropic viruses. This conclu-
sion is consistent with other studies that have found that 
ostensibly “resting” memory CD4+ T cells (i.e., those lacking 
conventional markers of cell activation) and activated mem-
ory CD4+ T cells, and not macrophages, are the principal early 
targets of HIV-1 and SIV infection in humans and primates 
(1, 2, 7, 29, 34–36).
Other biological properties of the three transmitted/
founder viruses that we studied included their sensitivity to 
a large number of Env-specific ligands (Table III). Viruses 
HIV-1pZM246F-10, HIV-1pZM247Fv1, and HIV-1pZM247Fv2 exhibited 
properties similar to viruses pseudotyped by other primary 
subtype B (11) or subtype C (37) HIV-1 Envs with respect to 
their CD4 and CCR5 dependence and sensitivity to the gp41 
peptide fusion inhibitors T20 and T1249 and to the MPER 
mAb 4E10. Only HIV-1pZM246F-10 was sensitive to B12, and 
none of the three were sensitive to 2G12 or 2F5, likely be-
cause of epitope variation on C clade viruses. The coreceptor 
binding surface of diverse HIV-1 strains is antigenically con-
served (38), as is the V3 loop (39, 40), but HIV-1pZM246F-10, 
HIV-1pZM247Fv1, and HIV-1pZM247Fv2 were resistant to CD4i 
Table III.  Phenotype of transmitted HIV-1 clade C viruses compared with prototype clade B viruses
Virusa sCD4 HIVIG Clade B 
plasma
Clade C 
plasma
17b 21c b12 2G12 2F5 4E10 Z13e1 447-
52D
447-
52D+  
sCD4
F425-
B4e8
F425-
B4e8+  
sCD4
3074 3074+ 
 sCD4
T-20 T-1249 Anti-
CD4 
mab
TAK-
779
Co-
receptor 
usage
nM µg/ml (IC50)b (IC50)c µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µM
YU-2 13 619 20 20 >10 >10 7.16 >50 >50 >50 >50 13.36 1.48 >25 1.85 >25 >25 0.49 0.094 0.18 0.047 R5
NL4.3 1 60 92 31 0.21 0.59 0.01 1.08 0.24 1.05 >50 0.03 0.01 >25 >25 >25 >25 0.47 0.003 0.63 >10 X4
ADA 105 1,000 19 17 >10 >10 1.31 >50 33.2 >50 >50 >25 0.03 >25 0.11 >25 6.81 0.15 0.094 0.31 0.307 R5
NL.Bal.  
ecto
8 113 50 32 >10 >10 0.11 1.39 12.3 15.1 >50 0.14 0.04 0.54 0.05 >25 1.47 0.09 0.015 0.44 1.04 R5
ZM246F 125 748 13 31 >10 >10 21.35 >50 >50 5.50 >50 >25 >25 >25 >25 >25 3.35 0.07 0.012 0.17 0.003 R5
ZM2 
47Fv1
155 >1,000 13 18 >10 >10 >50 >50 >50 11.33 >50 >25 >25 >25 >25 >25 >25 0.05 0.011 0.11 0.032 R5
ZM2 
47Fv2
125 >1,000 12 20 >10 >10 >50 >50 >50 47.11 >50 >25 >25 >25 >25 >25 >25 0.08 0.027 0.16 0.034 R5
aViruses derived by transfection of 293T cells with replication-competent molecularly cloned proviral DNA.
bReciprocal geometric mean neutralization titers (IC50) of heterologous plasma specimens from 11 HIV-1 clade B chronically infected subjects.
cReciprocal geometric mean neutralization titers (IC50) of heterologous plasma specimens from 22 HIV-1 clade C chronically infected subjects.1286 TRANSMITTED/FOUNDER VIRUSES IN ACUTE HIV-1 INFECTION | Salazar-Gonzalez et al.
in 1× Expand Long Template buffer 1 (1.75 mM MgCl2 final concentration), 
0.35 mM of each dNTP, 0.3 µM of forward primer 1.U5.B1F (5-CCTT-
GAGTGCTTCAAGTAGTGTGTGCCCGTCTGT-3; nt 538–571), re-
verse primer 1.R3.B3R, and 3.75 U/µl Expand Long Template Mix (Roche) 
in a 50-µl reaction mixture. The PCR mixtures were set up in optical 96-
well reaction plates (MicroAmp; Applied Biosystems) and sealed with Micro-
Amp adhesive film. PCR conditions were 94°C for 2 min, followed by 10 
cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 8 min, followed by 25 
cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 8 min, with cumulative 
increments of 20 s at 68°C with each successive cycle and a final extension 
period of 10 min at 68°C. Second-round PCR was performed by transfer-
ring 1 µl of the first-round product into a final volume of 50 µl of a reaction 
mixture containing 1× Expand Long Template buffer, 0.35 mM of each 
dNTP,  and  0.3  µM  of  forward  primer  2.U5.B4F  (5-AGTAGTGTGT-
GCCCGTCTGTTGTGTGACTC-3; nt 552–581) and reverse primer 
2.R3.B6R (5-TGAAGCACTCAAGGCAAGCTTTATTGAGGC-3; nt 
9,607–9,636). PCR conditions were the same as for the first-round PCR. 
The amplicons were sized on precast 1% agarose E-gel 48 (Invitrogen). All 
products derived from cDNA dilutions yielding < 20% PCR-positive wells 
and >7-kb in length by analytical gel electrophoresis were sequenced. Be-
cause genomic length viral RNA is flanked by the R region of the LTR, 
only partial LTR sequences and near-complete viral genomes can be ob-
tained in a single PCR amplification step. Specifically, the internal nested 5 
primer (2.U5.B4F) corresponds to the first 30 nt of U5 (HXB2 nt 552–581), 
and the internal nested 3 primer (2.R3.B6R) corresponds to the last 30 nt of 
the 3 R region (HXB2 nt 9,607–9,636), thus rendering these two short 
stretches of 30 nt primer derived rather than virus derived. To determine 
complete transmitted/founder viral RNA/cDNA sequences that include vi-
ral sequences occupied by 5 U5 and 3 R primers, a separate PCR reaction 
was performed using primers located in the 5 R region and in gag. For this 
amplification, nested PCR primers corresponded to the 5 R (HXB2 nt 
452–474 and 456–482) and gag (HXB2 nt 1,401–1,422 and 1,432–1,452), 
and a 1-kb amplicon was generated and sequenced. PCR reaction conditions 
were the same as for the full-length amplification except for a reduction in 
extension time to 1 min. Collectively, the resulting amplicons and sequences 
encompassed the complete HIV-1 viral genome. To amplify the complete 
HIV-1 genome in two partially overlapping 5-kb fragments, we modified 
the SGA procedure previously described for the HIV-1 env gene (11). PCR 
amplifications were performed in the presence of 1× High Fidelity Platinum 
PCR buffer, 2 mM MgSO4, 0.2 mM of each dNTP, 0.2 µM of each primer, 
and 0.025 U/µl Platinum Taq High Fidelity polymerase (Invitrogen) in a 
20-µl reaction. First-round PCR primers for amplifying the 5 half genome 
were 1.U5.B1F and B5R1. PCR reactions were performed in MicroAmp 
96-well reaction plates as follows: 1 cycle of 94°C for 2 min, and 35 cycles of 
a denaturing step of 94°C for 15 s, an annealing step of 55°C for 30 s, and an 
extension step of 68°C for 5 min, followed by a final extension of 10 min at 
68°C. 2 µl from the first-round PCR product was added to a second-round 
PCR that included the 5 half genome forward primer 2.U5.B4F and reverse 
primer B5R2 (5-CAATCATCACCTGCCATCTGTTTTCCATA-3; nt 
5,040–5,068). The second-round PCR reaction was performed under the 
same conditions indicated for the first-round PCR but with a total of 45 cy-
cles. To amplify the 3 half genome, first-round PCR primers included B3F1 
(5-ACAGCAGTACAAATGGCAGTATT-3; nt 4,749–4,771) and 1.
R3.B3. The first-round PCR reaction conditions were the same as for the 5 
half genome. Next, 2 µl from the first-round PCR product was added to a 
second-round  PCR  that  included  primers  B3F3  (5-TGGAAAGGT-
GAAGGGGCAGTAGTAATAC-3; nt 4,956-4,983) and 2.R3.B6R. PCR 
conditions were the same as for the second-round amplification of the 5 half 
genome. All products derived from cDNA dilutions yielding <30% PCR-
positive wells and >4-kb amplicons were sequenced. All PCR procedures 
were performed under PCR clean-room conditions (11).
DNA sequencing. Amplicons were directly sequenced, aligned, and analyzed 
as previously described (11, 50, 51). APOBEC-associated G-to-A hypermu-
tated sequences were identified and excluded from model analyses. The full 
this number increased to 17–34 selected sites. Elucidation of 
adaptive and innate immune pressures that act to shape the 
evolving virus quasispecies, ultimately affecting viral load set-
point and disease progression, is an important area for future 
investigation (22). Mapping mutations on a genome-wide 
basis against transmitted/founder virus sequences in recently 
infected individuals, including vaccine breakthrough infec-
tions, represents a unique strategy to explore the constellation 
of immune pressures acting on HIV-1 (8–12, 22), SIV (21), 
and other viral pathogens (41–43).
MATERIALS AND METHODS
Study subjects. Peripheral blood samples were obtained from 12 adult sub-
jects who gave informed consent under clinical protocols approved by the 
participating institutions’ human use review boards, including those at the 
University of Alabama at Birmingham, the University of North Carolina at 
Chapel Hill, Emory University, the Rockefeller University, and Duke 
University. Blood was generally collected in acid citrate dextrose and plasma 
separated and stored at 70°C.
Laboratory staging. Plasma samples were tested for HIV-1 RNA, p24 
antigen, and viral-specific antibodies as previously described (11, 17). The 
duration of the eclipse phase (the period between virus transmission and 
the detection of viral RNA in plasma) was estimated to be 10 d (range = 
7–21 d) (11, 44–49).
Viral RNA extraction and cDNA synthesis. Approximately 20,000 
viral RNA copies were extracted using the QIAamp Viral RNA Mini 
Kit (QIAGEN) or the BioRobot EZ1 Workstation with EZ1 Virus Mini 
Kit (version 2.0; QIAGEN). Samples with low vRNA loads (200–10,000 
copies/ml) were concentrated by centrifugation at 23,600 g for 1 h at 4°C 
before extraction. RNA was recovered from spin columns in a final elu-
tion volume of 60 µl. RNA was either frozen at 80°C or immediately 
used to synthesize cDNA. 5,000 (or fewer) vRNA molecules were reverse 
transcribed using SuperScript III according to the manufacturer’s instruc-
tions (Invitrogen) and modified as follows. RT reactions were performed 
in 40-µl reactions. First, 15 µl RNA was mixed with 11 µl of a master 
mix A containing 0.5 mM of each deoxynucleoside triphosphate (dNTP) 
and 0.25 µM of reverse primer 1.R3.B3R (5-ACTACTTGAAGCACT-
CAAGGCAAGCTTTATTG-3; nt 9,611–9,642; HXB2 numbering) and 
incubated for 5 min at 65°C to denature secondary RNA structure. cDNA 
generated by reverse primer 1.R3.B3R served as a template for PCR am-
plification of a 9-kb or a 5-kb fragment corresponding to the 3 half viral 
genome. A separate RT reaction was performed using reverse primer B5R1 
(5-CTTGCCACACAATCATCACCTGCCAT-3;  nt  5,052–5,077)  to 
generate cDNA that served as a template to amplify a 5-kb 5 half viral 
genome fragment. After denaturation, the tube was incubated on ice for   
1 min. Then, 26 µl of the reaction mixture was combined with a master mix 
B–containing RT buffer (1×), 5 mM dithiothreitol, 2 U/µl of the RNase 
inhibitor RNaseOUT, and 5 U/µl SuperScript III. Tubes were then incu-
bated at 50°C for 1.5 h. An additional 1 µl SuperScript III was added and 
tubes were incubated for another 1.5 h at 55°C. After the completion of 
the RT step, the reaction mixture was inactivated by heat (70°C for 15 min),   
followed by the addition of 1 µl RNase H, and incubated at 37°C for   
20 min. The resulting cDNA was aliquoted and frozen at 80°C until further 
analysis or used immediately for PCR amplification.
SGA. cDNA was serially diluted in replicates of eight PCR wells and sub-
jected to nested PCR amplification with HIV-specific primers that yield a 9-kb 
fragment beginning at the first nucleotide of the U5 region of the 5 long 
terminal repeat (LTR) and extending to the last nucleotide of the R region 
of the 3 LTR. cDNA dilutions that yielded 40% or fewer PCR-positive 
wells were retested in 96-well plates to identify a dilution where <20% of 
wells were positive for amplification products. First-round PCR was performed JEM VOL. 206, June 8, 2009 
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CAAAATGG-3; nt 9,689-del-9,719). PCR primers for variant 2 are 
V25F (5-TGGAAGGGTTAGTTTACTCCAAGAAAAGG-3; nt 1–29) 
and V25R (5-CATGGTGTTGGTATTATTGCTGGTAGCAG-3; nt 
6,643-del-6,686), and V23F (5-GGCTCCATAGCTTAGGGCAACATA-
TCTATA-3; nt 5,671–5,700) and V23R (5-TGCTAGAGATTTTCCA-
CACTACCAAAATGG-3; nt 9,689-del-9,719). PCR was performed under 
the following conditions: 1 cycle of 99°C for 1 min, and 35 cycles of 99°C for 
8 s, 65°C for 30 s, and a 72°C extension for 4 min, followed by a final exten-
sion of 72°C for 10 min. Correctly sized fragments (6 kb for 5 and 4 kb 
for 3) were identified by gel electrophoresis. An adenine overhang was added 
to each purified fragment using Taq polymerase with 1× buffer (Promega) 
and 0.2 mM of each dNTP incubated at 94°C for 2 min followed by a single 
extension of 72°C for 10 min. Each half genome was then independently T/A 
cloned into the TOPO-XL vector (Invitrogen) and transformed into XL2-
Blue MRF competent bacteria (Agilent Technologies). Bacteria were plated 
on lysogeny broth (LB) agar plates supplemented with 50 µg/ml kanamycin 
and cultured overnight at 30°C. Single colonies were selected and grown 
overnight in liquid LB at 30°C with 225-rpm shaking followed by plasmid 
isolation. Each molecular clone was sequence confirmed to be identical to the 
transmitted/founder viral sequence for each lineage. The 5 clone for each lin-
eage was ligated to the cognate 3-XL vector by using PacI and MluI (variant 1)   
or NotI (variant 2) restriction digestion and ligation (New England Biolabs 
Inc.), thereby generating the infectious clones for lineage 1 (pZM247Fv1) and 
lineage 2 (pZM247Fv25).
Virus phenotypic analysis. The ability of cloned viral genomes to express 
replication-competent virus was assessed using 293T cells for DNA transfec-
tion and primary human CD4+ lymphocytes, monocyte-derived macro-
phages, and JC53BL-13 cells (TZM-bl; National Institutes of Health AIDS 
Research and Reference Reagent Program) as target cells, as previously de-
scribed (20, 52–54). Virus neutralization by Env-specific antibodies and li-
gands was similarly tested as previously described (11, 20, 38, 52). All samples 
were tested in duplicate and all experiments were repeated at least three 
times to ensure reproducibility.
Virus replication was assessed in activated primary human CD4+ T cells 
and in monocyte-derived macrophages obtained from the same normal hu-
man donors. Peripheral blood was collected into ACD-A anticoagulant by 
venipuncture and mononuclear cells (PBMCs) purified by standard Ficoll-
Hypaque density gradient methods. For CD4+ T cell isolation, PBMCs were 
incubated with human anti-CD4–coated magnetic beads (Militenyi Biotec) 
and positively selected using a cell separator (autoMACS; Militenyi Biotec). 
They were then incubated in 10-cm polystyrene tissue culture plates for 2 h 
at 37°C in HBSS with 10 mM Ca2+ and Mg2+ to remove adherent mono-
cytes. Nonadherent cells were collected, washed in RPMI 1640 plus 15% FBS, 
and resuspended at 106 cells/ml in RPMI 1640 plus 15% FBS with 3 µg/ml 
staphyloccocal enterotoxin B (Sigma-Aldrich) for 48 h at 37°C to activate 
the lymphocytes. 5 × 105 cells were incubated with 50,000 IU of virus over-
night at 37°C in 300 µl RPMI 1640 with 15% FBS. Cells were washed three 
times and plated in 24-well polystyrene tissue culture plates in a volume of 
2 ml RPMI 1640 with 15% FBS and 30 U IL-2/ml. 60 µl of media was re-
moved for day 1 p24 and RT baseline analysis. Every 3 d, 60 µl of media was 
removed and frozen for p24/RT analysis and half of the media was removed 
from each well and replaced with fresh media. For monocyte-derived macro-
phage isolation, 3 × 106 PBMCs per well were plated in 24-well plates in 
HBSS plus 10 mM Ca2+ and Mg2+ plus 10% human AB serum (Sigma-Aldrich) 
and incubated at 37°C for 2 h. Nonadherent cells were removed and DMEM 
with 10% giant cell tumor (GCT)–conditioned media (Irvine Scientific) plus 
10% human AB serum was added to wells with 5 U/ml rhMCSF (R&D 
Systems). After 3 d of incubation, wells were washed vigorously with PBS 
three times, and media containing DMEM with 10% GCT, 10% FBS, and 5 U 
rhMCSF was added to wells. After an additional 3 d of incubation, media 
was removed and macrophages were incubated with 100,000 IU of virus   
in 300 µl per well. After a 2-h incubation, 500 µl of media was added per 
well. After overnight incubation, each well was washed three times, 1.5 ml 
of media was added, and 60 µl of media was removed for day 1 p24/RT 
sequence alignment is available as a supplemental data file (www.hiv.lanl.gov/
content/sequence/hiv/user_alignments/Salazar), and sequences are available 
from  GenBank/EMBL/DDBJ  under  accession  nos.  FJ495804–FJ496214, 
EU578998–EU579004, EU579006–EU579015, EU579018–EU579019, 
EU576471–EU576521, and FJ919955–FJ919967.
Mathematical model. The model used in the present study has been fully 
described (11). Under this model, with no selection pressure and fast expan-
sion, one can expect small samples from homogeneous virus populations to 
have evolved from a founder strain in a star-like phylogeny, with all sequences 
coalescing at the founder (11, 21). Occasional deviations from a star phylog-
eny are, however, expected. The sampling of 10 sequences, for example, 
from a later generation of an exponentially growing population with sixfold 
growth per generation (R0 = 6) has 4% chance of including a pair sharing 
the first four generations, 19% chance of including sequences that share three, 
and 75% chance of sharing two. With a predicted rate of mutations of approx-
imately one per five generations for the full-length 9-kb HIV-1 genome, 
there is 75% chance of finding among 10 sequences 2 that share one muta-
tion, 20% chance of finding 2 sequences that share a pair of mutations, and 
<2% chance of sharing more than that. These probabilities are slightly en-
hanced by early stochastic events that can lead to the virus producing less 
than six descendants in some generations but are diminished by the chances 
that mutations cause a fitness disadvantage that results in early purifying se-
lection, as previously observed (11, 24).
Proviral DNA cloning. To obtain an infectious molecular clone of the 
transmitted/founder virus from subject ZM246F, the entire 9.7-kb sequence 
was first inferred from SGA analysis of plasma viral RNA and then chemi-
cally synthesized in three subgenomic fragments of 4, 2.6, and 3.1 kb (Blue 
Heron Biotechnology). These fragments overlapped at unique NheI (HXB2 
position 3,998) or DraIII (HXB2 position 6,600) sites, respectively, and were 
propagated in plasmid vectors. A 5 terminal MluI cloning site that was at-
tached during chemical synthesis and a BamHI polylinker site at the 3 end 
of the genome were used for subsequent manipulation. To facilitate assem-
bly of a full-length proviral clone, a unique MluI site was engineered by oli-
gonucleotide adapter ligation between EcoRI and HindIII of pBR322. The 
4-kb 5 fragment was then cloned in MluI-NheI of the modified pBR322 
vector. After restriction enzyme digestion of this recombinant plasmid with 
NheI and BamHI, the full-length proviral clone pZM246F-10 was generated 
by simultaneous ligation with the 2.6-kb middle NheI-DraIII and the 3.1-kb 
3 DraIII-BamHI fragments. The integrity of the entire proviral consensus 
sequence was confirmed by restriction endonuclease mapping, and finally, 
by nucleotide sequence analysis.
To obtain infectious molecular clones of the two transmitted/founder 
viruses from subject ZM247F, we used a high fidelity DNA polymerase and 
proviral DNA as a template to obtain both 5 and 3 half genomes, each 
with a complete LTR element. Primers were designed to correspond exactly 
to the transmitted/founder sequence as determined by SGA-direct amplicon 
sequencing. For the 5 half genome, the entire 5 U3-R-U5, gag, pol, vif, vpr 
tat1, rev1, and vpu, and part of env were amplified in a single-round PCR. 
For the 3 half genome, the entire 3 U5-R-U3, nef, tat2, and rev2, and the 
remainder of env were amplified. High molecular weight genomic DNA was 
isolated from PBMCs obtained on the same day that plasma virus was used 
to identify the two unique transmitted/founder virus lineages. The complete 
proviral genomes corresponding to both virus lineages were amplified and 
cloned in two overlapping halves encompassing a unique restriction site, PacI. 
Single-round PCR amplification was performed in the presence of 1× Phu-
sion Hot Start HF Buffer, 0.2 mM of each dNTP, 0.5 µM of each primer,   
3% final concentration of DMSO, and 0.02 U/µl Phusion Hot Start High 
Fidelity DNA polymerase (New England Biolabs, Inc.) in a 40-µl reaction. 
PCR primers for the variant 1 are V15F (5-TGGAAGGGTTAATTTAC-
TCCAAGAAAAGG-3; nt 1–29; HXB2 numbering) and V15R (5-CAC-
TGTCTTCTGCCCTTTCTCTAATTCTTT-3;  nt  6,192–6,221),  and 
V13F  (5-TAGGAAATTGGTAAGACAAAGAAAAATAGACTGG-3; 
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baseline analysis. Every 3 d, 60 µl of culture supernatant was removed and 
frozen for p24/RT analysis, whereas the remainder of the media was re-
moved from each well and replaced with 1.5 ml of fresh media. Cultures 
were continued for 16 d.
Online supplemental material. Fig. S1 shows phylogenetic and Highlighter 
analyses  of  HIV-1  sequences  from  subjects  SUMA0847,  TRJO4551, 
04013396-0,  and  ZM249M.  Fig.  S2  shows  phylogenetic  and  Highlighter 
analyses of HIV-1 sequences from subjects ZM246F, CH58, 04013226-2, 
and WEAU0575. Fig. S3 shows nucleotide sequence alignments of poly-
morphic regions in env and nef in early samples from subject CH40. Fig. S4 
shows nucleotide sequence alignments of polymorphic regions in tat and env 
in early samples from subject CH77. Fig. S5 shows nucleotide sequence 
alignments of polymorphic regions in pol in early samples from subject 
CH77. Fig. S6 shows nucleotide sequence alignments of polymorphic re-
gions in pol in early samples from subject CH58. Table S1 shows nucleotide 
gene diversity in four protein-coding regions in early progeny of transmit-
ted/early founder viruses. Table S2 provides an analysis of pn and ps for gag, 
pol, env, and nef. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20090378/DC1.
We thank D. McPherson, Y. Chen, and B. Cochran for technical assistance; the clinical 
cores of the Center for HIV/AIDS Vaccine Immunology and the University of Alabama 
at Birmingham Center for AIDS Research; and J. White for manuscript preparation.
This work was supported by the Center for HIV/AIDS Vaccine Immunology and 
by grants from the National Institutes of Health (AI067854, AI061734, and AI27767) 
and the Bill and Melinda Gates Foundation (37874).
The authors have no conflicting financial interests.
Submitted: 17 February 2009
Accepted: 1 May 2009
REFERENCES
  1.  Brenchley, J.M., T.W. Schacker, L.E. Ruff, D.A. Price, J.H. Taylor, 
G.J. Beilman, P.L. Nguyen, A. Khoruts, M. Larson, A.T. Haase, and 
D.C. Douek. 2004. CD4+ T cell depletion during all stages of HIV 
disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 
200:749–759. 
  2.  Haase, A.T. 2005. Perils at mucosal front lines for HIV and SIV and 
their hosts. Nat. Rev. Immunol. 5:783–792.
  3.  Margolis, L., and R. Shattock. 2006. Selective transmission of CCR5-
utilizing HIV-1: the ‘gatekeeper’ problem resolved? Nat. Rev. Microbiol. 
4:312–317. 
  4.  Mehandru, S., M.A. Poles, K. Tenner-Racz, A. Horowitz, A. Hurley, 
C. Hogan, D. Boden, P. Racz, and M. Markowitz. 2004. Primary HIV-1   
infection is associated with preferential depletion of CD4+ T lym-
phocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 
200:761–770. 
  5.  Pope,  M.,  and  A.T.  Haase.  2003.  Transmission,  acute  HIV-1  in-
fection and the quest for strategies to prevent infection. Nat. Med. 
9:847–852. 
  6.  Shattock, R.J., and J.P. Moore. 2003. Inhibiting sexual transmission of 
HIV-1 infection. Nat. Rev. Microbiol. 1:25–34. 
  7.  Veazey, R.S., I.C. Tham, K.G. Mansfield, M. DeMaria, A.E. Forand, 
D.E. Shvetz, L.V. Chalifoux, P.K. Sehgal, and A.A. Lackner. 2000. 
Identifying the target cell in primary simian immunodeficiency virus 
(SIV) infection: highly activated memory CD4(+) T cells are rapidly 
eliminated in early SIV infection in vivo. J. Virol. 74:57–64. 
  8.  Abrahams, M.R., J.A. Anderson, E.E. Giorgi, C. Seoighe, K. Mlisana, 
L.-H. Ping, G.S. Athreya, F.K. Treurnichat, B.F. Keele, N. Wood, et al. 
2009. Quantitating the multiplicity of infection with human immuno-
deficiency virus type 1 subtype C reveals a non-poisson distribution of 
transmitted variants. J. Virol. 83:3556–3567. 
  9.  Haaland,  R.E.,  P.A.  Hawkins,  J.  Salazar-Gonzalez,  A.  Johnson,  A. 
Tichacek, E. Karita, O. Manigart, J. Mulenga, B.F. Keele, G.M. Shaw, 
et al. 2009. Inflammatory genital infections mitigate a severe genetic 
bottleneck in heterosexual transmission of subtype A and C HIV-1. 
PLoS Pathog. 5:e1000274. JEM VOL. 206, June 8, 2009 
ARTICLE
1289
low neutralizing potency in acute infection and following vaccination. 
Virology. 387:414–426.
  41.  Kuntzen, T., J. Timm, A. Berical, L.L. Lewis-Ximenez, A. Jones, B. 
Nolan, J. Schulze zur Wiesch, B. Li, A. Schneidewind, A.Y. Kim, R.T. 
Chung, G.M. Lauer, and T.M. Allen. 2007. Viral sequence evolution in 
acute hepatitis C virus infection. J. Virol. 81:11658–11668. 
  42.  Morimoto, K., D.C. Hooper, H. Carbaugh, Z.F. Fu, H. Koprowski, 
and B. Dietzschold. 1998. Rabies virus quasispecies: implications for 
pathogenesis. Proc. Natl. Acad. Sci. USA. 95:3152–3156. 
  43.  Towner, J.S., M.L. Khristova, T.K. Sealy, M.J. Vincent, B.R. Erickson, 
D.A. Bawiec, A.L. Hartman, J.A. Comer, S.R. Zaki, U. Stroher, et al. 
2006. Marburgvirus genomics and association with a large hemorrhagic 
fever outbreak in Angola. J. Virol. 80:6497–6516. 
  44.  Clark, S.J., M.S. Saag, W.D. Decker, S. Campbell-Hill, J.L. Roberson, 
P.J. Veldkamp, J.C. Kappes, B.H. Hahn, and G.M. Shaw. 1991. High 
titers of cytopathic virus in plasma of patients with symptomatic primary 
HIV-1 infection. N. Engl. J. Med. 324:954–960.
  45.  Gaines, H., M. von Sydow, P.O. Pehrson, and P. Lundbegh. 1988. 
Clinical picture of primary HIV infection presenting as a glandular-
fever-like illness. BMJ. 297:1363–1368. 
  46.  Lindbäck, S., A.C. Karlsson, J. Mittler, A. Blaxhult, M. Carlsson, G. 
Briheim, A. Sonnerborg, and H. Gaines. 2000a. Viral dynamics in pri-
mary  HIV-1  infection.  Karolinska  Institutet  Primary  HIV  Infection 
Study Group. AIDS. 14:2283–2291. 
  47.  Lindbäck,  S.,  R.  Thorstensson,  A.C.  Karlsson,  M.  von  Sydow,  L. 
Flamholc, A. Blaxhult, A. Sonnerborg, G. Biberfeld, and H. Gaines. 
2000b. Diagnosis of primary HIV-1 infection and duration of follow-up 
after HIV exposure. Karolinska Institute Primary HIV Infection Study 
Group. AIDS. 14:2333–2339. 
  48.  Little, S.J., A.R. McLean, C.A. Spina, D.D. Richman, and D.V. Havlir. 
1999. Viral dynamics of acute HIV-1 infection. J. Exp. Med. 190:841–850. 
  49.  Schacker, T., A.C. Collier, J. Hughes, T. Shea, and L. Corey. 1996. 
Clinical and epidemiologic features of primary HIV infection. Ann. 
Intern. Med. 125:257–264.
  50.  Maddison,  W.P.,  and  D.R.  Maddison.  2001.  MacClade  4:  Analysis 
of  Phylogency  and  Character  Evolution.  Sinauer  Associates,  Inc., 
Sunderland, MA. 503 pp.
  51.  Thompson, J.D., D.G. Higgins, and T.J. Gibson. 1994. CLUSTAL W: 
improving the sensitivity of progressive multiple sequence alignment 
through sequence weighting, position-specific gap penalties and weight 
matrix choice. Nucleic Acids Res. 22:4673–4680. 
  52.  Wei, X., J.M. Decker, H. Liu, Z. Zhang, R.B. Arani, J.M. Kilby, 
M.S. Saag, X. Wu, G.M. Shaw, and J.C. Kappes. 2002. Emergence 
of resistant human immunodeficiency virus type 1 in patients receiv-
ing fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 
46:1896–1905. 
  53.  Mascola, J.R., P. D’Souza, P. Gilbert, B.H. Hahn, N.L. Haigwood, L. 
Morris, C.J. Petropoulos, V.R. Polonis, M. Sarzotti, and D.C. Montefiori. 
2005. Recommendations for the design and use of standard virus panels 
to assess neutralizing antibody responses elicited by candidate human im-
munodeficiency virus type 1 vaccines. J. Virol. 79:10103–10107. 
  54.  Li,  M.,  F.  Gao,  J.R.  Mascola,  L.  Stamatatos,  V.R.  Polonis,  M. 
Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K.M. Greene, et al. 2005. 
Human immunodeficiency virus type 1 env clones from acute and early 
subtype  B  infections  for  standardized  assessments  of  vaccine-elicited 
neutralizing antibodies. J. Virol. 79:10108–10125. 
  27.  Wei,  X.,  S.K.  Ghosh,  M.E.  Taylor,  V.A.  Johnson,  E.A.  Emini,  P. 
Deutsch, J.D. Lifson, S. Bonhoeffer, M.A. Nowak, B.H. Hahn, et al. 
1995. Viral dynamics in human immunodeficiency virus type 1 infec-
tion. Nature. 373:117–122. 
  28.  Ho, D.D., A.U. Neumann, A.S. Perelson, W. Chen, J.M. Leonard, 
and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 
lymphocytes in HIV-1 infection. Nature. 373:123–126. 
  29.  Hladik, F., P. Sakchalathorn, L. Ballweber, G. Lentz, M. Fialkow, D. 
Eschenbach,  and  M.J.  McElrath.  2007.  Initial  events  in  establishing 
vaginal entry and infection by human immunodeficiency virus type-1. 
Immunity. 26:257–270. 
  30.  Duenas-Decamp, M.J., P. Peters, D.R. Burton, and P.R. Clapham. 
2009. Determinants flanking the CD4 binding loop modulate macro-
phage-tropism of HIV-1 R5 envelopes. J. Virol. 83:2575–2583. 
  31.  Dunfee,  R.L.,  E.R.  Thomas,  P.R.  Gorry,  J.  Wang,  J.  Taylor,  K. 
Kunstman, S.M. Wolinsky, and D. Gabuzda. 2006. The HIV Env vari-
ant N283 enhances macrophage tropism and is associated with brain 
infection and dementia. Proc. Natl. Acad. Sci. USA. 103:15160–15165. 
  32.  Peters, P.J., W.M. Sullivan, M.J. Duenas-Decamp, J. Bhattacharya, C. 
Ankghuambom, R. Brown, K. Luzuriaga, J. Bell, P. Simmonds, J. Ball, 
and P.R. Clapham. 2006. Non-macrophage-tropic human immuno-
deficiency virus type 1 R5 envelopes predominate in blood, lymph 
nodes, and semen: implications for transmission and pathogenesis. J. Virol. 
80:6324–6332. 
  33.  Xu, Y., H. Zhu, C.K. Wilcox, A. van’t Wout, T. Andrus, N. Llewellyn, 
L. Stamatatos, J.I. Mullins, L. Corey, and T. Zhu. 2008. Blood mono-
cytes harbor HIV type 1 strains with diversified phenotypes including 
macrophage-specific CCR5 virus. J. Infect. Dis. 197:309–318. 
  34.  Mattapallil, J.J., D.C. Douek, B. Hill, Y. Nishimura, M. Martin, and M. 
Roederer. 2005. Massive infection and loss of memory CD4+ T cells in 
multiple tissues during acute SIV infection. Nature. 434:1093–1097. 
  35.  Schacker, T., S. Little, E. Connick, K. Gebhard, Z.Q. Zhang, J. Krieger, 
J. Pryor, D. Havlir, J.K. Wong, R.T. Schooley, et al. 2001. Productive 
infection of T cells in lymphoid tissues during primary and early human 
immunodeficiency virus infection. J. Infect. Dis. 183:555–562. 
  36.  Veazey, R.S., M. DeMaria, L.V. Chalifoux, D.E. Shvetz, D.R. Pauley, 
H.L. Knight, M. Rosenzweig, R.P. Johnson, R.C. Desrosiers, and A.A. 
Lackner. 1998. Gastrointestinal tract as a major site of CD4+ T cell 
depletion and viral replication in SIV infection. Science. 280:427–431. 
  37.  Li, M., J.F. Salazar-Gonzalez, C.A. Derdeyn, L. Morris, C. Williamson, 
J.E. Robinson, J.M. Decker, Y. Li, M.G. Salazar, V.R. Polonis, et al. 2006. 
Genetic and neutralization properties of subtype C human immunodefi-
ciency virus type 1 molecular env clones from acute and early heterosexu-
ally acquired infections in Southern Africa. J. Virol. 80:11776–11790. 
  38.  Decker, J.M., F. Bibollet-Ruche, X. Wei, S. Wang, D.N. Levy, W. 
Wang, E. Delaporte, M. Peeters, C.A. Derdeyn, S. Allen, et al. 2005. 
Antigenic conservation and immunogenicity of the HIV coreceptor 
binding site. J. Exp. Med. 201:1407–1419. 
  39.  Davis, K.L., F. Bibollet-Ruche, H. Li, J.M. Decker, O. Kutsch, L. 
Morris, A. Salomon, A. Pinter, J.A. Hoxie, B.H. Hahn, et al. 2009. 
Human  immunodeficiency  virus  type  2  (HIV-2)/HIV-1  envelope 
chimeras detect high titers of broadly reactive HIV-1 V3-specific anti-
bodies in human plasma. J. Virol. 83:1240–1259. 
  40.  Davis, K.L., E.S. Gray, P.L. Moore, J.M. Decker, A. Salomon, D.C. 
Montefiori, B.S. Graham, M.C. Keefer, A. Pinter, L. Morris, et al. 
2009. High titer HIV-1 V3-specific antibodies with broad reactivity but 